PURPOSE OF REVIEW: This review highlights current features of the changing landscape of the US population with newly diagnosed prostate cancer and discusses new treatment options utilizing noninvasive or minimally invasive management. RECENT FINDINGS: Recent evidence of significant changes in the current prostate cancer landscape is based on clinical data and pathological specimens after radical prostatectomy that suggest a further increase of the low-risk patient population that may require reconsideration of treatment options. For a select cohort of patients with low-risk features, based on the D'Amico definition, active surveillance or focal ablative therapy may be a rational alternative to surgical prostatectomy or whole-gland radiation therapy that still dominate as the main treatment approaches for localized prostate cancer. SUMMARY: As the prostate-specific antigen era continues to mature, we continue to witness stage migration. A growing segment of the localized prostate cancer patient population has very low-volume, low-grade disease. Although active surveillance may be an appropriate approach for a selected group of patients, the progression requiring whole-gland therapy remains a challenge. Organ-sparing focal therapy might ideally fill the gap between a surveillance strategy and whole-gland treatment providing a reasonable balance between cancer control and quality of life.
PURPOSE OF REVIEW: This review highlights current features of the changing landscape of the US population with newly diagnosed prostate cancer and discusses new treatment options utilizing noninvasive or minimally invasive management. RECENT FINDINGS: Recent evidence of significant changes in the current prostate cancer landscape is based on clinical data and pathological specimens after radical prostatectomy that suggest a further increase of the low-risk patient population that may require reconsideration of treatment options. For a select cohort of patients with low-risk features, based on the D'Amico definition, active surveillance or focal ablative therapy may be a rational alternative to surgical prostatectomy or whole-gland radiation therapy that still dominate as the main treatment approaches for localized prostate cancer. SUMMARY: As the prostate-specific antigen era continues to mature, we continue to witness stage migration. A growing segment of the localized prostate cancerpatient population has very low-volume, low-grade disease. Although active surveillance may be an appropriate approach for a selected group of patients, the progression requiring whole-gland therapy remains a challenge. Organ-sparing focal therapy might ideally fill the gap between a surveillance strategy and whole-gland treatment providing a reasonable balance between cancer control and quality of life.
Authors: R Jason Stafford; Anil Shetty; Andrew M Elliott; Sherry A Klumpp; Roger J McNichols; Ashok Gowda; John D Hazle; John F Ward Journal: J Urol Date: 2010-08-19 Impact factor: 7.450
Authors: Deborah J del Junco; Erin E Fox; Sharon Cooper; Marc Goldhagen; Erik Koda; David Rogers; Edith Canby-Hagino; Jeri Kim; Curtis Pettaway; Douglas D Boyd Journal: J Urol Date: 2011-04-15 Impact factor: 7.450
Authors: P Castelo-Branco; B J Passer; J S Buhrman; S Antoszczyk; M Marinelli; C Zaupa; S D Rabkin; R L Martuza Journal: Gene Ther Date: 2010-03-11 Impact factor: 5.250
Authors: Donna P Ankerst; Jing Xia; Ian M Thompson; Josef Hoefler; Lisa F Newcomb; James D Brooks; Peter R Carroll; William J Ellis; Martin E Gleave; Raymond S Lance; Peter S Nelson; Andrew A Wagner; John T Wei; Ruth Etzioni; Daniel W Lin Journal: Eur Urol Date: 2015-03-25 Impact factor: 20.096